Episode 172 - February 6, 2026

The Biotech Hangout panel discusses the resurgence of biotech IPOs, noting a potential indicator of market health and maturity with companies launching with late-stage assets and tested platforms. They highlight the diversity of therapeutic areas attracting investment, including oncology, ophthalmology, dermatology, and the growing innovation in immunology and inflammation. The panel also analyzes Amgen's challenge to the FDA's request to withdraw Tavneos, a rare disease drug, sparking debate about data integrity and regulatory overreach. The discussion shifts to the obesity market, addressing the FDA's stance against companies mass-marketing compounded versions of GLP-1 drugs and the competitive landscape between Eli Lilly and Novo Nordisk. Finally, the panel touches on GSK's decision to relinquish rights to Wave Life Sciences for a rare disease drug, raising questions about pharma's shifting priorities.